Any travel requires some planning, especially if youre going camping, hiking, or doing other activities outdoors. When you have ulcerative colitis (UC), you need to think even more about where to go, what to pack, and how to find the nearest bathroom. Continue reading →

A recent study found that maintaining ulcerative colitis (UC) remission was significantly more common in patients who continued treatment with infliximab, compared to those who discontinued treatment. The use of anti-tumor necrosis factor (TNF) agents is common in the treatment of refractory UC, but the long-term use of anti-TNF therapy can increase the risk of malignancy or infection. Continue reading →

Deucravacitinib could soon be coming for a chunk of these. However, safety is still the big unknown for the Bristol project Continue reading →

"You're too young to be that sick." That is what my former gastroenterologist said to me when I was first diagnosed with ulcerative colitis sometime around 2000. Continue reading →

People who take a commonly-prescribed drug for inflammatory bowel disease (IBD) should not assume they are protected after a first dose of Covid-19 vaccine, say the authors of a large-scale study that found many had poor antibody responses. Continue reading →

Crohns disease is a type of inflammatory bowel disease (IBD) that causes chronic inflammation in the digestive tract. Continue reading →

The recent report on Ulcerative Colitis Treatment Market Report 2021 by Key Players, Types, Applications, Countries, Market Size, forecast to 2027 offered by Credible Markets, comprises of a comprehensive investigation into the geographical landscape, industry size along with the revenue estimation of the business. Additionally, the report also highlights the challenges impeding market growth and expansion strategies employed by leading companies in the Ulcerative Colitis Treatment Market. An exhaustive competition analysis that covers insightful data on industry leaders is intended to help potential market entrants and existing players in competition with the right direction to arrive at their decisions. Continue reading →

According to the Centers for Disease Control and Prevention (CDC), in 2015, 1.3% of US adults (3 million) reported that they were diagnosed with IBD (either Crohns disease or UC). Continue reading →

BLACKSBURG, Va., April 26, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced that two late-breaking abstracts on preclinical data of omilancor in psoriasis and proof-of concept preclinical data of PX-69 in rheumatoid arthritis will be presented at the upcoming American Association of Immunologists (AAI) Annual Meeting 2021. The meeting will be held virtually from May 10-15, 2021 Continue reading →